ReferenceID 231
Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis
Oncoimmunology
Myeloid-derived suppressor cells (MDSCs) are a major component of the immunosuppressive tumor microenvironment and has been recognized as a contributing factor for inflammation-related cancers. We previously showed that
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 231
- Evidence Id
- 16821
- Core Evidence Id
- 16821
- Source Reference Id
- 423
- Herb2 Reference Id
- HBREF000740
- Subject Paper Key
- HBIN025026_30377563
- Pubmed Id
- 30377563
- Doi
- 10.1080/2162402X.2018.1498437
- Paper Title
- Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis
- Paper Abstract
- Myeloid-derived suppressor cells (MDSCs) are a major component of the immunosuppressive tumor microenvironment and has been recognized as a contributing factor for inflammation-related cancers. We previously showed that embelin has potent anti-inflammatory and anti-tumor effects in a colitis-associated cancer (CAC) model. Here, by using this model, we assessed the effect of embelin on the accumulation and suppressive function of MDSCs. We have demonstrated that embelin substantially reduced accumulation of MDSCs in the peripheral lymphoid organ and tumor tissue of CAC-bearing mice. Embelin impaired immunosuppressive activity of MDSCs by reducing the generation of reactive oxygen species (ROS) and arginase 1 level, leading to restored T cell responses. In tumor milieu, embelin increased the infiltration of CD8+ T cells, NK cells and mature dendritic cells whilst depleted the regulatory T cells. Moreover, embelin could directly interfere with the generation and function of MDSCs in vitro. These effects of embelin on MDSCs were mediated largely via limiting C/EBPβ and STAT3 signaling. Our findings support the hypothesis that embelin may be a promising pharmacologic agent in regulating MDSC-mediated immune tolerance in colorectal cancer.
- Journal
- Oncoimmunology
- Publish Year
- 2018
- Experiment Subject
- mouse
- Experiment Type
- Animal Experiment
- Phenotype Related
- Colorectal Cancer
- Paper Title Cn
- Paper Title En
- Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis
- Bilingual Status
- semi_complete